These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 11693902)

  • 1. Antiangiogenic scheduling of lower dose cancer chemotherapy.
    Gately S; Kerbel R
    Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The possible role of chemotherapy in antiangiogenic drug resistance.
    Bocci G; Loupakis F
    Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis research: guidelines for translation to clinical application.
    Folkman J; Browder T; Palmblad J
    Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic dosing of chemotherapy: applications in pediatric oncology.
    Stempak D; Seely D; Baruchel S
    Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.
    Samuel DP; Wen PY; Kieran MW
    Expert Opin Investig Drugs; 2009 Jul; 18(7):973-83. PubMed ID: 19548852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of antiangiogenic therapy with other modalities.
    O'Reilly MS
    Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of angiogenesis in cancer patients.
    Verheul HM; Pinedo HM
    Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy.
    Shaked Y; Kerbel RS
    Cancer Res; 2007 Aug; 67(15):7055-8. PubMed ID: 17671170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
    Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
    Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
    Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
    Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
    Plavetić ND; Letilović T; Vrbanec D
    Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.